A new paper by an international group of researchers from several different centers has maybe identified a new way to differentiate accurately between indolent and aggressive forms of prostate cancer at time of initial diagnosis. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: aggressive, expression, EZH2, gene, indolent, risk, TOP2A | 1 Comment »
The most frequent alteration in the prostate oncogenome is loss of chromosome (chr) 8p21 that has been associated with loss of NKX3.1 homeobox gene.
… READ MORE …
Filed under: Drugs in development | Tagged: EMT, expression, miR-3622a, transition | Leave a comment »
Drugs like docetaxel and cabazitaxel (taxanes) are among the most active forms of treatment in the management of men with metastatic, castration-resistant prostate cancer (mCRPC), but they don’t work for everyone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cabazitaxel, docetaxel, expression, gene, taxane, TMPRSS2-ERG | Leave a comment »
A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate cancer (and in related clinical trials). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, cell, circulating, CTC, expression, liquid, PTEN, tumor | 2 Comments »
A newly published paper in Science Translational Medicine has added to our understanding of the future potential of liquid biopsies (e.g., blood, plasma, and similar samples) in the management of progressive forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, biopsy, expression, liquid, plasma, receptor | Leave a comment »
Although it has no immediate relevance to the treatment of prostate cancer, it is worth noting that the results of the very first, completed and published “basket” type of clinical trial appear in this week’s issue of the New England Journal of Medicine (NEJM). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: basket, expression, gene, outcome, targeted, therapy, trial | 6 Comments »
This, of course, is a rhetorical question. We really have no good idea how many “different” types of prostate cancer there are. And so what we are really dealing with here is how we are going to sub-classify prostate cancers in the future in order to treat them most appropriately at the earliest relevant stage of development. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: expression, genetic, genomic, outcome, profiling, risk | 1 Comment »
A new paper by Cuzick and colleagues has suggested that loss of expression of the PTEN gene, which encodes for a protein known as phosphatase and tensin homologue (PTEN), may be significantly associated with heightened risk of progressive disease in a cohort of nominally low-risk patients. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, expression, outcome, PTEN, risk, Treatment | Leave a comment »
An article just published on the Medscape web site addresses data on the potential of GenomeDx Bioscence’s new “Decipher” test which “could” (according to one urologic oncologist) help prevent over-treatment of at least some men with prostate cancer. One might ask whether we can — as yet — decipher the value of the Decipher test. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Decipher, expression, gene, risk, Treatment | 2 Comments »
According to a media release from the Mayo Clinic earlier today, “Alterations to the ‘on-off’ switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches.” … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: aggressiveness, DNA, expression, gene, methylation, test | 2 Comments »
“Manserin” is a novel peptide originally derived from a larger secretory protein called secretogranin II. A newly published paper suggests that expression of manserin in human prostate cancer tissues may correlate with risk for clinically significant and progressive forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: expression, Gleason, immunohistochemistry, manserin, progression, risk | Leave a comment »
According to a report in the Science section of the Financial Times, “the world’s first nationwide genetic testing programme for cancer patients goes into action in the UK next month, with support from the public, private and charitable sectors.” … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, expression, gene, genetics, Management, risk | Leave a comment »
There are in fact three so-called “isozymes” (slightly different versions) of the human enzyme 5α-steroid reductase. The activity of 5α-reductase-II can be affected by the 5α-reductase inhibitor (5-ARI) finasteride (Proscar); the activity of 5α-reductase-I and -II can be affected by the 5-ARI dutasteride (Avodart), but … READ MORE …
Filed under: Drugs in development, Prevention | Tagged: 5α-reductase, expression, inhibition | 1 Comment »
As usual, some of our friends in the media are over-hyping a recent publication about the possible effects of a protein called FUS/TLS in the progression of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: expression, FUS, FUS/TLS, progression, protein | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 